Enspryng (satralizumab) / Roche |
| Terminated | 4 | 4 | Europe, Canada, Japan, US, RoW | Satralizumab 120 mg | Hoffmann-La Roche, Chugai Pharmaceutical Co. | Neuromyelitis Optica Spectrum Disorder, NMOSD | 10/23 | 10/23 | | |
2020-004436-21: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia Gravis |
|
|
| Ongoing | 3 | 240 | Europe | Satralizumab, RO5333787, Injection | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Generalized Myasthenia Gravis (gMG), Myasthenia gravis is a rare neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis affecting multiple muscle groups throughout the body is called gMG., Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento |
|
|
| Not yet recruiting | 3 | 100 | Europe | satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng | F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | 3 | 8 | Europe | Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04963270 / 2020-004436-21: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis |
|
|
| Active, not recruiting | 3 | 185 | Europe, Canada, Japan, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche, Chugai Pharmaceutical | Generalized Myasthenia Gravis | 01/24 | 09/24 | | |
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Completed | 3 | 119 | Europe, Canada, Japan, US, RoW | satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder | 05/24 | 05/24 | | |
NCT05987423: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease |
|
|
| Recruiting | 3 | 120 | Europe, Japan, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche | Thyroid Eye Disease, TED | 03/25 | 05/26 | | |
SatraGO-2, NCT06106828: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease |
|
|
| Recruiting | 3 | 120 | Europe, Canada, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche | Thyroid Eye Disease | 05/25 | 05/26 | | |
Cielo, NCT05503264 / 2021-002395-39: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis |
|
|
| Recruiting | 3 | 152 | Europe, Japan, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche, Chugai Pharmaceutical Co. | NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis | 06/25 | 12/27 | | |
Meteoroid, NCT05271409 / 2021-003192-34: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease |
|
|
| Recruiting | 3 | 152 | Europe, Canada, Japan, US, RoW | Satralizumab, Placebo | Hoffmann-La Roche, Chugai Pharmaceutical | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | 07/26 | 12/28 | | |
|
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 3 | 8 | Europe, US, RoW | Satralizumab | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder, NMOSD | 03/27 | 09/29 | | |
| Recruiting | 2 | 40 | Europe, Canada | Satralizumab Prefilled Syringe, Placebo Comparator | Centre Hospitalier Universitaire de Nice | Facioscapulohumeral Muscular Dystrophy 1 | 01/27 | 01/27 | | |
SHIELD DMD, NCT06450639: An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy |
|
|
| Not yet recruiting | 2 | 50 | US | Satralizumab | Hoffmann-La Roche | Duchenne Muscular Dystrophy | 06/26 | 06/27 | | |
| Recruiting | 2 | 20 | Japan | Satralizumab (Genetical Recombination) | International University of Health and Welfare, Japan Agency for Medical Research and Development, Keio University, Chugai Pharmaceutical | Pulmonary Arterial Hypertension | 06/26 | 06/26 | | |
| Ongoing | 1 | 0 | RoW | SA237 | Chugai Pharma | Rheumatoid Arthritis | | | | |
| Not yet recruiting | 1 | 15 | US | Satralizumab | University of Florida, Genentech, Inc. | Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia | 07/26 | 12/26 | | |